Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
IRINOTECAN HYDROCHLORIDE TRIHYDRATE
Actavis Group hf
L01XX19
IRINOTECAN HYDROCHLORIDE TRIHYDRATE
20 Mg/Ml
Concentrate for Soln for Inf
Product subject to prescription which may not be renewed (A)
Other antineoplastic agents
Authorised
2008-05-16
V033_AUGUST 15 IRINOTECAN HYDROCHLORIDE 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION Irinotecan hydrochloride trihydrate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor. • If any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1 WHAT IRINOTECAN IS AND WHAT IT IS USED FOR 2 WHAT YOU NEED TO KNOW BEFORE YOU USE IRINOTECAN 3 HOW TO USE IRINOTECAN 4 POSSIBLE SIDE EFFECTS 5 HOW TO STORE IRINOTECAN 6 CONTENTS OF THE PACK AND OTHER INFORMATION 1 WHAT IRINOTECAN IS AND WHAT IT IS USED FOR Irinotecan belongs to a group of medicines called cytostatics (anti-cancer medicines). Irinotecan is used for the treatment of advanced cancer of the colon and rectum in adults, either in a combination with other medicines or alone. 2 WHAT YOU NEED TO KNOW BEFORE YOU USE IRINOTECAN DO NOT USE IRINOTECAN IF YOU • are allergic to irinotecan hydrochloride trihydrate or any of the other ingredients of this medicine (listed in section 6) • if you have any other bowel disease or a history of bowel obstruction • if you are pregnant or breast feeding • if you have increased levels of bilirubin in the blood (more than 3 times the upper limit of normal) • if you have severe bone marrow failure • if you are in a poor general health (evaluated by an international standard) • if you are using the natural remedy St Johns‟ Wort _(Hypericum perforatum) _ _ _ WARNINGS AND PRECAUTIONS Talk to your doctor before using. This medicine is intended for adults only. Special care is needed in older patients. Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Irinotecan Hydrochloride 20 mg/ml concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of concentrate contains 20mg Irinotecan hydrochloride trihydrate equivalent to 17.33 mg/ml irinotecan. Each 2ml or 5ml or 25ml vial of Irinotecan Hydrochloride contains 40mg, 100mg or 500mg of Irinotecan hydrochloride trihydrate respectively. Excipients with known effect: Sorbitol E420 For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for infusion: A clear, colourless to slightly yellow solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion is indicated for the treatment of patients with advanced colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease, - as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. Irinotecan in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. Irinotecan in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Recommended dosage_ _In monotherapy (for previously treated patient)_ The recommended dosage of irinotecan hydrochloride trihydrate is 350 mg/m² administered as an intravenous infusion over a 30- 90 minute period every three weeks (see below “Method of administration” and section 4.4 and 6.6). _In combination the Read the complete document